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Abstract
Background: GPR88 is an orphan G protein-coupled receptor highly expressed in the striatum and is implicated in
basal ganglia-associated disorders. However, the receptor functions of GPR88 are still largely unknown due to
the lack of potent and selective ligands appropriate for central nervous system investigation. Development of a
high-throughput screening assay for GPR88 should facilitate the discovery of novel ligands to probe GPR88
functions.
Methods: In this paper, we describe the development of a CHO-Gαqi5-GPR88 cell-based calcium mobilization
assay. The assay takes advantage of functional coupling of GPR88 with the promiscuous Gαqi5 protein and
consequent mobilization of intracellular calcium, which can be measured in a 384-well format with a Fluorescent
Imaging Plate Reader.
Results: The CHO-Gαqi5-GPR88 cell-based calcium mobilization assay was validated by the structure-activity
relationship study of known GPR88 agonist (1R,2R)-2-PCCA analogues. The assay was automated and
miniaturized to a 384-well format, and was deemed robust and reproducible with a Z’-factor of 0.72 and
tolerated dimethyl sulfoxide to a final concentration of 2%. Screening a pilot neurotransmitter library
consisting of 228 compounds yielded 10 hits, but none of the hits were confirmed as GPR88 agonists in
follow-up assays.
Conclusions: We have developed a high-throughput calcium mobilization assay for the orphan receptor
GPR88. This calcium mobilization assay can be used to identify several different types of GPR88 ligands
including agonists, competitive and noncompetitive antagonists, inverse agonists, and allosteric modulators.
These ligands will serve as valuable tools to probe signaling mechanisms and in vivo functions of GPR88,
and could expedite development of novel therapies for diseases potentially mediated by GPR88.
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Background
Basal ganglia dysfunction is implicated in a number of
neurological and psychiatric disorders including Parkinson’s
and Huntington’s diseases, schizophrenia, bipolar disorder,
and drug abuse [1]. Although dopaminergic and gluta-
matergic systems are often used as drug targets to treat
basal ganglia-associated disorders [2, 3], considerable efforts
have also focused on identifying alternative mechanisms
and new candidate proteins that regulate basal ganglia
functions, which may lead to new drug discovery opportun-
ities [4, 5]. The orphan G protein-coupled receptor (GPCR)
GPR88 is a potential candidate for such efforts.
GPR88 is highly expressed in striatal GABAergic
medium spiny neurons (MSNs), which are involved in
both the striatonigral and striatopallidal pathways [6–8].
GPR88 is also expressed in other brain regions including
the cerebral cortex, amygdala, and hypothalamus [9–11].
Multiple lines of evidence obtained from GPR88-
knockout studies suggest that GPR88 plays an important
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role in regulating striatal functions and is implicated in
basal ganglia-associated disorders. In past studies,
GPR88-knockout mice demonstrated disrupted prepulse
inhibition of startle response, a phenotype of schizophrenia,
and exhibited D2 receptor hypersensitivity, as evidenced by
increased sensitivity to amphetamine-stimulated locomotor
activity and to apomorphine-induced climbing and stereo-
typy [12]. In a different study, GPR88-deficient mice exhib-
ited increased locomotion, poor motor coordination and
impaired cue-based learning, which could be normalized by
targeted viral expression of the receptor in striatal MSNs
[8]. A recent study also linked GPR88 to anxiety disorders,
as the GPR88-knockout mice exhibited low anxiety com-
pared to wild-type animals [13].
We previously reported that a synthetic small molecule
(1R,2R)-2-PCCA [(1R,2R)-2-(pyridin-2-yl)cyclopropanecar-
boxylic acid ((2S,3S)-2-amino-3-methylpentyl)-(4’-propylbi-
phenyl-4-yl)amide] was able to modulate GPR88 activity.
This agonist inhibited isoproterenol-stimulated cAMP
accumulation with an EC50 = 603 nM in a GloSensor
cAMP assay using stable HEK293-GPR88-pGloSensor22F
cells, suggesting GPR88 is coupled to Gαi proteins [14].
Recently, we showed that (1R,2R)-2-PCCA had an EC50 =
56 nM, in line with the EC50 value reported by Bi et al.
[15], in a LANCE® Ultra cAMP assay using stable PPLS-
HA-GPR88 CHO cells [16]. The discrepancy between the
EC50 values of (1R,2R)-2-PCCA is possibly due to the
sensitivity of the different assay systems. Another type
of compound structurally related to 2-PCCA, represented
by 2-AMPP [(2S)-N-((1R)-2-amino-1-(4-(2-methylpentylox-
y)phenyl)ethyl)-2-phenylpropanamide], was also shown to
activate GPR88 [17, 18]. Although (1R,2R)-2-PCCA is
useful in the characterization of in vitro signaling
pathways of GPR88, it may not be as useful as an in
vivo probe due to its high lipophilicity (cLogP 6.19) and
reports that it is a P-glycoprotein substrate, both of which
indicate that the compound is expected to have poor brain
penetration [15]. Clearly, there is an unmet need for
GPR88 in vivo probes appropriate for CNS investigation.
Structurally different chemotypes with better drug-like
characteristics showing potent and selective GPR88 agon-
ism/antagonism will be particularly helpful in this regard.
Development of a high-throughput screening (HTS) assay
for GPR88 should facilitate the discovery of novel ligands
as in vivo probes of GPR88 function. Herein we report the
development of a calcium mobilization based HTS assay
for GPR88, which was validated by the structure-activity




(1R,2R)-2-PCCA (1a, Table 1) and analogues (1b-d, 2a-c
and 3) were synthesized following methods detailed in
our early work [14, 16]. All target compounds were
characterized by NMR and HRMS analyses, and the
spectral data were in agreement with the assigned struc-
tures (see Additional file 1).
Cell culture and molecular biology
Cell culture materials were purchased from Fisher SSI.
Lipofectamine LTX with PLUS reagent was purchased
from ThermoFisher Scientific. FuGene was purchased
from Promega. Gαqi5-CHO stable cells were purchased
from GenScript (Piscataway, NJ) and were cultured in
Ham’s F12 supplemented with 10% fetal bovine serum
(FBS), 100 units each of penicillin and streptomycin (P/
S), and 100 μg/mL Hygromycin B. An expression plas-
mid containing a pre-prolactin leader sequence (PPLS)
and an influenza hemagglutanin (HA) tag fused in frame
upstream of the human GPR88 cDNA was prepared in a
modified pcDNA3.1+ mammalian expression vector by
GenScript. Midi-prep DNA was prepared using a Qiagen
HiSpeed Plasmid Midi Kit and the PPLS-HA-GPR88
construct was verified by sequencing.
Transient transfections
CHO-RD-HGA16 (Molecular Devices) cells stably ex-
pressing the Gαq16 protein were plated into 6-well dishes
at 200,000 cells/well and incubated at 37 °C, 5% CO2
overnight. The next day, cells were transfected with an
expression vector containing human GPR88 cDNA
(1000 ng) using FuGene. The next day, cells were lifted
and plated into 96-well black-walled clear bottom assay
plates and the calcium mobilization assay (as described
in the 96-well methods) was run the following day using
10 μM final (1R,2R)-2-PCCA to stimulate the cells.
Gαqi5-CHO cells were plated into 6-well dishes at
250,000 cells/well and incubated at 37 °C, 5% CO2
overnight. The next day, cells were transfected with an
expression vector containing human PPLS-HA-GPR88
cDNA (2500 ng) using Lipofectamine LTX with PLUS
reagent. Transfected cells were plated and assayed as
described for the Gαq16 cells.
Creation of stable PPLS-HA-GPR88-Gαqi5-CHO cell line
Gαqi5-CHO cells were transfected with PPLS-HA-GPR88
using Lipofectamine LTX with PLUS reagent. Transfected
cells were plated into 10 cm2 dishes 24 h post transfection
and were selected using Geneticin. After 2 weeks, individ-
ual clones were selected, grown to confluence, and
screened in a functional 96-well calcium mobilization
assay that measured response to (1R,2R)-2-PCCA (10 μM
final). Concentration-response curves of (1R,2R)-2-PCCA
were run in clones that showed a high response to the
agonist in the screen. The final working clone with the
most potent (1R,2R)-2-PCCA response and the largest
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signal window (EC50 = 468 nM; signal window = 6000
RFU) was chosen for all subsequent studies.
96-well calcium mobilization assay
The day before the assay, stable PPLS-HA-GPR88-
Gαqi5-CHO cells were plated into 96-well black-walled
assay plates at 30,000 cells/well (100 μL per well) in
Ham’s F12 supplemented with 10% FBS and 100 units
each of P/S. The cells were incubated overnight at 37 °C,
5% CO2. Prior to the assay, Calcium 5 dye (Bulk Kit,
Molecular Devices) was reconstituted according to the
manufacturer’s instructions. The reconstituted dye was
diluted 1:40 in pre-warmed (37 °C) assay buffer (1X
HBSS, 20 mM HEPES, 2.5 mM probenecid, pH 7.4 at
37 °C). Medium was removed from the plate, and the
cells were gently washed with 100 μL of pre-warmed
(37 °C) assay buffer. The diluted Calcium 5 dye (200 μL)
was added and the cells were incubated for 45 min at
37 °C, 5% CO2. During the incubation, serial dilutions of
(1R,2R)-2-PCCA were prepared in 0.25% BSA/1%
DMSO/assay buffer, aliquoted into 96-well polypropyl-
ene plates, and warmed to 37 °C. After the dye-loading
incubation period, the cells were pretreated with 25 μL
of 2.25% BSA/9% DMSO/assay buffer and incubated for
15 min at 37 °C. After the pretreatment incubation
period, the plate was read with a FlexStation II (Molecu-
lar Devices). Calcium-mediated changes in fluorescence
were monitored every 1.52 s over a 60 s time period,
with the FlexStation II adding 25 μL of test compound
dilutions at the 19 s time point (excitation at 485 nm,
detection at 525 nm). Peak kinetic reduction (SoftMax,
Molecular Devices) relative fluorescent units (RFU) were
plotted against the log of compound concentration using
nonlinear regression analysis to generate EC50 values
(GraphPad Prism 6.0, GraphPad Software, Inc., San
Diego, CA).
Tolerance to DMSO
Tolerance to DMSO was determined by evaluating the
(1R,2R)-2-PCCA response at multiple final concentra-
tions of DMSO (1, 1.5, 2, 2.5, 3, 3.5%) in the functional
calcium mobilization assay.
384-well Z’-factor determination and no-wash calcium
mobilization protocol
The stable PPLS-HA-GPR88-Gαqi5-CHO cells were
plated in 30 μL/well volume at 9000 cells/well in Ham’s
F12 medium supplemented with 1% FBS and 100 units
each of P/S in 384-well Greiner μClear® black walled
microplates using a MicroFlo™ Select dispenser fitted
with a 5 μL cassette (BioTek). The plated cells were
incubated overnight at 37 °C, 5% CO2. The next day,
Calcium 5 dye (Bulk Kit, Molecular Devices) was recon-
stituted according to the manufacturer’s instructions.
The reconstituted dye was diluted 1:20 in pre-warmed
(37 °C) assay buffer (1X HBSS, 20 mM HEPES, 2.5 mM
Table 1 EC50 determination of (1R,2R)-2-PCCA analogues
Compda X R1 R2 pEC50 (EC50, nM)
b
(1R,2R)-2-PCCA (1a) N Propyl 6.33 ± 0.06 (468)
1b C Propyl 5.90 ± 0.08 (1260)
1c C Cyclohexyl 6.10 ± 0.04 (794)
1d C CONH2 NA
c
2a (S)-NH2 5.88 ± 0.03 (1320)
2b (R)-NH2 5.58 ± 0.04 (2630)
2c H NAc
3 NAc
aAll compounds were tested as the HCl salt
bpEC50 values are means ± standard error of at least three independent experiments performed in duplicate
cEC50 > 10 μM, tested in two independent experiments performed in duplicate
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probenecid, pH 7.4 at 37 °C) and 30 μL was add to the
plate (no-wash protocol), which was then incubated for
45 min at 37 °C, 5% CO2. During the incubation, 10 μM
of (1R,2R)-2-PCCA was prepared at 10x the desired final
concentration in 0.25% BSA/2% DMSO/assay buffer, ali-
quoted into 384-well polypropylene plates, and warmed
to 37 °C. Using the Fluorescent Imaging Plate Reader
(FLIPR) Tetra (Molecular Devices), the dye loaded plate
was pretreated with 8.5 μL 2% BSA/16% DMSO/assay
buffer and incubated for 15 min at 37 °C, 5% CO2. After
this incubation period, the plate was read with the Tetra.
Calcium-mediated changes in fluorescence were moni-
tored every 1 s over a 60 s time period, with the Tetra
adding 8.5 μL of (1R,2R)-2-PCCA or 0.25% BSA/2%
DMSO/assay buffer at the 10 s time point (excitation at
470-495 nm, detection at 515-575 nm). Data was
collected in ScreenWorks version 3.2 (Molecular
Devices). The bias was subtracted on image 8 and the
maximum-minimum relative fluorescent units (RFU)
statistic was used to calculate the Z’-factor [19] using




the mean, μ is the standard deviation, agonist is the
signal produced by (1R,2R)-2-PCCA and control is
the vehicle (0.25% BSA/2% DMSO/assay buffer).
HTS of a pilot neurotransmitter library
The PPLS-HA-GPR88-Gαqi5-CHO cells were used to
screen a small neurotransmitter library purchased from
Enzo Life Sciences (cat. BML-2811, BML-2813 and
BML-2819; 228 compounds, Farmingdale, NY). The
mother plates from this library were compressed and
replicated into 384-well polypropylene daughter plates
containing 1 μL of compound at 10 mM in 100%
DMSO. All plates were heat sealed with an Agilent
Technologies PlateLoc sealer and were stored at -20 °C.
Columns 1-2 and 23-24 were left empty during the
compression/replication process for assay controls. All
compound library plates were barcoded for tracking
purposes; plate barcodes link compound identities in
RTI International’s institutional database, ChemCart
(DeltaSoft).
On each day of the primary screen, the daughter plates
with 1 μL of compound were thawed, spun at 1000 rpm
for 3 min, unsealed, diluted with 49 μL 0.25% BSA/assay
buffer, and mixed using a Biomek NX fitted with a 384
multi-channel dispense head (Beckman Coulter). Assay
controls, consisting of a concentration-response curve of
(1R,2R)-2-PCCA, 10 μM final (1R,2R)-2-PCCA, and
0.25% BSA/2% DMSO/assay buffer, were added to
columns 1, 2, 23, and 24 of each plate and each plate
was kept at 37 °C. The assay was run and the data
were collected as described in the 384-well methods
section. The raw RFUs for each compound were con-





Creation of stable PPLS-HA-GPR88-Gαqi5-CHO cell line and
development of calcium mobilization assay for GPR88
Recently, we have demonstrated that GPR88 couples to
Gαi and functionally inhibits cAMP production upon
activation by the agonist (1R,2R)-2-PCCA [14]. In
addition, 2-PCCA does not induce calcium mobilization
in GPR88 cells, indicating that GPR88 is likely not
coupled to Gαq proteins. With these factors in mind, a
heterologous system was designed in which GPR88
could couple to the promiscuous Gαq subunit in CHO
cells to induce intracellular calcium mobilization. To de-
termine which promiscuous G protein would be most
effective for GPR88, we transiently transfected Gαq16
and Gαqi5 cells with GPR88 and tested the response to
10 μM (1R,2R)-2-PCCA in a calcium mobilization assay
(Fig. 1). In the Gαq16-GPR88 transients, (1R,2R)-2-PCCA
produced a large calcium mobilization signal; however, a
slightly stronger signal was also produced in the Gαq16
mock cells, indicating that (1R,2R)-2-PCCA does not
elicit a GPR88-specific response in the engineered Gαq16
system. In the Gαqi5-GPR88 transients, (1R,2R)-2-PCCA
produced a 2.3-fold specific response compared to the
Gαqi5 mock cells, thus suggesting that this engineered
system is suitable for stable cell line creation to monitor
GPR88 activity.
Gαqi5-CHO cells were transfected with a mammalian
expression plasmid containing the PPLS and HA epitope
tag fused in frame upstream of GPR88. The PPLS was
used to help promote transport of GPR88 to the plasma
membrane [20]. Transfected cells were kept in antibiotic
Fig. 1 Response of GPR88-Gαq16 and GPR88-Gαqi5 transients to (1R,2R)-
2-PCCA. Mock cells and GPR88 transfected cells were stimulated with
10 μM final (1R,2R)-2-PCCA 48 h after transfection in a calcium
mobilization assay. Representative data are shown and each bar is the
mean ± SD of duplicate determinations
Decker et al. Journal of Biomedical Science  (2017) 24:23 Page 4 of 9
selection for 2 weeks, after which individual clones were
selected and tested in a functional calcium mobilization
assay. Stimulation with 10 μM final (1R,2R)-2-PCCA
resulted in a calcium mobilization response mediated
through coupling of GPR88 with Gαqi5 as expected. After
evaluating 82 clones, a single clone with the most potent
EC50 value (468 nM) and the largest signal window (6000
RFU) was selected as our working clone (Fig. 2).
Effect of solvent on assay performance
The effect of DMSO on the assay’s performance was
evaluated at multiple final concentrations (1, 1.5, 2, 2.5,
3, 3.5%). This study used 1% DMSO as the lowest
concentration because most compound libraries are
supplied at 10 mM in DMSO and screened at 10 μM
final. As shown in Fig. 3, the assay’s performance was
not critically affected up to 1.5% final DMSO concentra-
tion, indicating that a final screening concentration of
10 μM is achievable with this assay. At 2% final DMSO,
the maximum response to (1R,2R)-2-PCCA decreased
by 1.4-fold, but was still appropriate for screening,
indicating that compounds can be screened at a final
concentration of 20 μM. Starting at 2.5% final DMSO,
the response was adversely affected due to a decline in
cell health after being exposed to higher concentrations
of DMSO.
Assay validation
To further validate the function of GPR88 in our stable
cell line, we tested a series of (1R,2R)-2-PCCA analogues
in the calcium mobilization assay. The results are reported
in Table 1. (1R,2R)-2-PCCA (1a) had an EC50 = 468 nM,
comparable to our previously reported EC50 of 603 nM in
a GloSensor cAMP assay using stable GPR88-pGloSen
sor22F cells [14]. In general, the SAR trends observed in
the calcium mobilization assay are in good agreement
with the results previously reported using cAMP assays
[14–16]. These comparison results further validate the
GPR88-Gαqi5 calcium assay as being capable of measuring
activity of GPR88 agonists.
HTS assay development
To make our 96-well calcium mobilization assay more
amenable to HTS, we automated and miniaturized the
assay to 384-well. Multiple cell densities were tested in
384-well format to determine the optimal number of
cells to use for screening, which was determined to be
9000 cells/well based on the assay’s signal window and
(1R,2R)-2-PCCA EC50 value. Automated cell dispensing
methods were examined by running the calcium
mobilization assay with cells plated with a MicroFlo
Select dispenser; those results were compared to results
obtained with manually plated cells. Further, compound
dispense heights and speeds were optimized on the
FLIPR Tetra to ensure proper dispensing without
disturbing the cell monolayer. Additionally, we tested
the effect of a no-wash protocol in which the calcium
dye is added directly to the growth media containing
the cells, thus making the assay procedure more
amenable to HTS. No adverse effects of the no-wash
protocol were observed; therefore, all subsequent
assays in 384-well format were conducted in this
manner. Using the fully optimized assay, we generated
a Z’-factor [19] by running at least two 384-well
plates containing positive ((1R,2R)-2-PCCA) and nega-
tive (2% DMSO/assay buffer) controls each day for
4 days. Although all of our efforts thus far used 1%
DMSO, we needed to increase the amount to 2% in
order to accommodate a final screening concentration
Fig. 3 DMSO sensitivity. The effect of DMSO on the assay’s signal
window was evaluated by stimulating cells with 10 μM final (1R,2R)-
2-PCCA containing varied DMSO concentrations (1, 1.5, 2, 2.5, 3, 3.5%
final). The assay performance is not critically affected up to 1.5%
DMSO. Representative data from one experiment are shown
Fig. 2 Concentration-response curve of (1R,2R)-2-PCCA in
PPLS-HA-GPR88-Gαqi5-CHO cells. Data points are means ± SEM of
three independent experiments run in duplicate in the working
clone. EC50 = 468 nM
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of 20 μM. Representative data from one plate are
shown in Fig. 4. On this plate, the average 10 μM
(1R,2R)-2-PCCA signal was 1830 RFU with a standard
deviation of 119 RFU and the average vehicle signal
was 199 RFU with a standard deviation of 24 RFU;
the Z’-factor was 0.74. The average Z’-factor ± SD from all
the experiments was calculated to be 0.72 ± 0.07. A Z’-fac-
tor > 0.5 is appropriate for a HTS assay; therefore, our
assay is deemed to be highly robust and reproducible, and
hence suitable for HTS applications.
Screening of a pilot neurotransmitter library
A small neurotransmitter library (228 compounds, Enzo
Life Sciences) was screened using the automated, miniatur-
ized PPLS-HA-GPR88-Gαqi5-CHO calcium mobilization
assay. All compounds were screened for agonist activity at
20 μM final concentration using (1R,2R)-2-PCCA as a
positive control. Agonist screening data were collected and
converted to % (1R,2R)-2-PCCA Emax. Screening of the
library yielded 10 compounds that increased fluorescence
to >50% of the (1R,2R)-2-PCCA control (Fig. 5). However,
a counter-screen against parental Gαqi5 cells suggested that
the hits were false positives due to nonspecific mobilization
of intracellular calcium.
Discussion
GPCRs have attracted significant attention for drug disco-
very due to their numerous physiological and pathological
roles in mediating cellular responses to hormones and
neurotransmitters [21]. Within the large GPCR family, 140
GPCRs, excluding olfactory receptors, are classified as
orphan receptors because their endogenous ligands are still
unknown [22]. GPR88 is one of these orphan GPCRs that
has recently attracted considerable interest because of its
linkage to a number of basal ganglia-associated disorders.
Despite the emerging pharmacological implications, the
detailed functions of GPR88 are still largely unknown due
to the lack of potent and selective ligands appropriate for
CNS investigation. The availability of a simple, rapid and
robust assay to monitor GPR88 activity would expedite the
search for novel GPR88 ligands. Thus, the goal of this
project was to develop a validated HTS assay for GPR88.
HTS campaigns for orphan GPCRs utilizing the meas-
urement of intracellular calcium mobilization with FLIPR
is a cost-effective, robust, and reproducible functional
assay. Because calcium mobilization occurs after activa-
tion of Gαq-coupled receptors and not all receptors couple
to Gαq, including GPR88 [14], a group of promiscuous
Gαq proteins was developed to enable GPCRs to mobilize
calcium. Gαq16 is the most widely used promiscuous Gαq
protein; [23] however, not all receptors couple effectively
to Gαq16 [24]. To circumvent this issue, the promiscuous
Gαqi5 protein was created to more effectively couple Gαi-
coupled receptors to Gαq proteins by replacing the five
Gαq C-terminal amino acids with those from the Gαi pro-
tein, thus allowing the Gαi-coupled receptor to respond to
an agonist via elevation of intracellular calcium [25, 26].
In order to develop a sensitive and reliable assay applic-
able for HTS, we tested different cell systems and initially
transfected GPR88 in Gαq16 and Gαqi5 CHO cells to deter-
mine which Gαq protein would couple with GPR88 to
induce calcium mobilization. Interestingly, we found that
the GPR88 receptor agonist (1R,2R)-2-PCCA did not elicit
a GPR88-specific response in the Gαq16 system, but did
elicit a specific response in the Gαqi5 system (Fig. 1). In
view of these findings, we created a stable PPLS-HA-
GPR88-Gαqi5 CHO cell line for the calcium mobilization
assay. The PPLS has been reported to enhance surface ex-
pression of a number of Gαi-coupled GPCRs [20, 27, 28],
and therefore was used to promote GPR88 expression on
the plasma membrane. In the stable PPLS-HA-GPR88-
Gαqi5 CHO cells, (1R,2R)-2-PCCA had a robust signal
with an EC50 = 468 nM. Although the response to
(1R,2R)-PCCA was potent in our calcium mobilization
assay, the concentration-response curve did not reach a
top plateau. We believe this is due to the engineered G
protein coupling present in the system as (1R,2R)-PCCA
is a highly potent agonist that reaches a top plateau in our
secondary cAMP assay [14, 16].
To further validate our stable GPR88 cell line, a number
of (1R,2R)-2-PCCA analogues were tested to characterize
their responses at GPR88 (Table 1). The phenyl analogue
1b was approximately 2.5-fold less potent than (1R,2R)-2-
PCCA. A large alkyl group such as cyclohexyl (1c, EC50 =
794 nM) was well tolerated at the 4’-position of the
biphenyl moiety. However, substitution with an amide
group (1d) resulted in a loss of activity. In an examination
of the amino alkyl side chain’s effect on potency, the
Fig. 4 Z’-factor of 384-well assay. The Z’-factor was determined for
the automated 384-well calcium mobilization assay by using (1R,2R)-
2-PCCA (○) as the positive control and 2% final DMSO as the negative
control (□) on at least two plates each day for four individual days.
Representative data are shown and each data point on the graph
is the response from a single well on one plate
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leucine derivative 2a had an EC50 value similar to the iso-
leucine analogue 1b (1320 nM vs 1260 nM). Changing the
S-configuration of the amino group to the R-configuration
(2b) led to a 2-fold loss of potency. Moreover, the isohexyl
compound 2c was completely inactive, indicating the
amino group is critical for activity, possibly because it
forms a hydrogen bonding interaction with the receptor
binding site. Finally, the (R,R)-configuration of the
cyclopropyl is also critical for activity as its (S,S)-iso-
mer resulted in an inactive compound 3. In general,
the SAR trends presented herein agree with the data
reported from the past studies [14–16]. In addition,
compounds were also tested in the parental Gαqi5
CHO cells and exhibited no activity at 10 μM final
concentration (see Additional file 1: Figure S1). Taken
together, these studies indicated that coupling to
Gαqi5 did not affect functional activation of GPR88
and that the calcium mobilization assay was capable
of detecting GPR88 agonists. The 96-well assay was
then optimized and adapted for HTS applications by
miniaturizing to 384-well and testing multiple variables
(cell density, solvent tolerance, and no-wash protocol).
The assay was deemed robust and reproducible with a Z’-
factor of 0.72 ± 0.07, and performed well with the no-wash
protocol in buffer containing DMSO at a final concentra-
tion up to 2%.
GPR88 is most closely related to the biogenic amine
receptors, and has the highest sequence homology with the
5-HT1d receptor and the β3 adrenergic receptor (27 and
21% identity, respectively) [6]. Chemogenomic analysis,
based on the alignment of 30 critical residues predicted
to line the binding cavity of GPCRs, clustered GPR88
with metabotropic glutamate and GABAB receptors,
suggesting they may bind to structurally related ligands
[29]. Accordingly, a pilot neurotransmitter library,
including natural and synthesized ligands of adrenergic,
serotonergic and GABAB receptors, was screened and
yielded 10 hits, but none of the hits were confirmed as
GPR88 agonists in follow-up assays. A larger HTS
campaign in the future using a more diverse set of com-
pounds that occupy different chemical spaces might lead
to the discovery of novel GPR88 agonists.
To the best of our knowledge, this is the first report
describing the development and validation of a GPR88
HTS assay. The only other scientific document outlining
such efforts is a university thesis available online through
the Leiden University Repository [30]. This report describes
efforts in the development of a calcium mobilization assay
for GPR88 using the promiscuous Gαq proteins (Gαq16 or
Gαqi5) in HEK293 cells; however, no known GPR88 ligands
were used to validate the assay. Furthermore, the report’s
stable GPR88-Gαqi5-HEK293 cells suffered loss of GPR88
expression over time, as only 40% of the cell population
was positive for GPR88 expression 3 weeks after fluorescent
automated cell sorting (FACS) enrichment [30]. Interest-
ingly, during the course of developing our GPR88 assays,
we independently observed that HEK293 cells physically
appeared unhealthy shortly after transfection with GPR88
and hence produced deteriorated responses to the agonist
(1R,2R)-2-PCCA over time. Due to those complications, we
opted to use GPR88-CHO cells for our HTS assay.
Recent efforts in our laboratory have focused on the
development of cAMP assays for the orphan GPR88
[14, 16, 18]. While the cAMP assay is a sensitive assay
platform that measures GPR88 activation, using this
platform for HTS has one major drawback. Because the
cAMP assay is an endpoint assay, only one mode of
activity can be measured in this format in a single
screen. Our laboratory is interested in identifying mul-
tiple types of ligands for GPR88, so developing a HTS
Fig. 5 Scatter plot of screening a pilot neurotransmitter library. The primary screen was conducted as described in the Methods. Each data point
represents a single well on a 384-well plate. (1R,2R)-2-PCCA and 0.25% BSA/2% DMSO (vehicle) are included as controls
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assay that can measure more than one mode of activity
at a time was highly desirable. Our laboratory has de-
veloped a general FLIPR-based calcium mobilization
protocol which allows for both agonist and antagonist
screening with a single assay plate, thereby cutting
screening time in half.
Conclusions
In conclusion, we have developed a CHO-Gαqi5-GPR88
cell-based calcium mobilization assay for the orphan
receptor GPR88. The assay was validated by the SAR
study of a small group of (1R,2R)-2-PCCA analogues,
and was deemed robust and suitable for HTS applica-
tions. Although our work thus far has been aimed at the
identification of GPR88 receptor agonists, in theory, this
calcium mobilization assay can be used to identify other
ligands as well, including competitive and noncompeti-
tive antagonists, inverse agonists and allosteric modula-
tors. These ligands will serve as valuable tools to probe
signaling mechanisms and in vivo functions of GPR88,
and could expedite development of novel therapies for
diseases potentially mediated by GPR88. Such efforts are
currently under investigation in our laboratory.
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